Table 1.

Expression of HM1.24 and the Sensitivity to Humanized Anti-HM1.24 MoAb of Neoplastic Myeloma Cells

Target Cells HM1.24 Expression (MSFI) Cytotoxicity (%)
Control Human IgGHumanized Anti-HM1.24
ARH-77  43  2  44  
IM-9 38  6  61  
RPMI 8226  36  0  37  
Ramos  33 0  33  
U 266  30  38* 59  
HS-Sultan 21  0  31  
Daudi  12  0  11  
Patient no. 1 34  4  29  
  1 25 
Patient no. 2  33  0  21  
  0 27 
Patient no. 3  30  0  16  
Patient no. 4  30  32  
CHO-1  50 5  38  
CHO-2 20 11  28  
CHO-3  5 7  
CHO-4  1 0  1  
HEL  11-153 
Target Cells HM1.24 Expression (MSFI) Cytotoxicity (%)
Control Human IgGHumanized Anti-HM1.24
ARH-77  43  2  44  
IM-9 38  6  61  
RPMI 8226  36  0  37  
Ramos  33 0  33  
U 266  30  38* 59  
HS-Sultan 21  0  31  
Daudi  12  0  11  
Patient no. 1 34  4  29  
  1 25 
Patient no. 2  33  0  21  
  0 27 
Patient no. 3  30  0  16  
Patient no. 4  30  32  
CHO-1  50 5  38  
CHO-2 20 11  28  
CHO-3  5 7  
CHO-4  1 0  1  
HEL  11-153 

HM1.24 expression was examined by flow cytometry. Cytotoxicity against tumor cells was determined by a 4-hour 51Cr-release assay using normal human PBMCs as effector cells at an E/T ratio of 50 in the presence of 1 μg/mL control human IgG or humanized anti-HM1.24 MoAb. Data represent the mean value of three independent experiments. The standard error of cytotoxicity was <10% in all target cells.

*

U266 is NK-sensitive.

Autologous PBMCs were used as effector cells.

CHO transformants expressing different levels of HM1.24 antigen were used.

F1-153

HEL does not express HM1.24 antigen.

or Create an Account

Close Modal
Close Modal